The pathologic classification of nonsmall cell lung cancer (NSCLC) is evolving. Lung adenocarcinoma is morphologically heterogeneous, with mixtures of acinar, papillary, bronchioloalveolar, and solid patterns in more than 80% of cases. In case of synchronous or metachronous multiple NSCLC, the distinction of intrapulmonary metastases from independent primary tumors is of great clinical importance as it influences staging and potentially the therapeutic strategy. Here we took advantage of a cohort of 20 patients with 42 multiple NSCLC tumors (24 potential pair comparisons) that were annotated molecularly using genomic and mutational profiling to evaluate the value of comprehensive histologic assessment in this setting. Using the Martini-Melamed criteria, paired tumors were characterized as multiple primary NSCLCs in 21 cases and as intrapulmonary metastases in 3 cases. Genomic and mutational data led to a diagnosis of multiple primaries in 14 cases and of metastases in 8 cases; 2 cases could not be assessed. This molecular characterization contradicted the Martini-Melamed diagnosis in 7 (32%) of the 22 assessable comparisons. Adenocarcinoma was found in 32 (76%) of the 42 tumors. After review in a blinded fashion, semiquantitative comprehensive histologic assessment of paired tumors was different in 16 and similar in 8 paired tumors. We found that comparing adenocarcinomas is a complex issue that requires assessment not only of percentages of the histologic subtypes, but also the recording of additional histologic details such as cytologic features, patterns of stroma, necrosis, discrete nodularity versus miliary growth and variants such as clear cell, signet ring, mucinous, and fetal patterns. We also found that paired squamous cell carcinomas could be compared based on histologic subtyping in addition to cytologic and stromal characteristics. Considering histologically different tumors as multiple primaries, and similar tumors as metastases, comprehensive histologic subtyping was consistent with the molecular characterization in 20 (91%) of the 22 pairs comparisons. In summary, based on a well characterized cohort with detailed clinical, pathologic and molecular data, we found comprehensive histologic assessment is a powerful tool that seems to be a promising way to determine whether multiple lung adenocarcinomas or squamous cell carcinomas are metastatic or multiple primaries. This has great clinical implications for staging and therapeutic management of lung cancer patients with multiple tumors. Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem.
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receptor (EGFR) mutations are more frequent in tumors with predominant papillary and bronchioloalveolar patterns, 2, 9, 13 KRAS mutations in mucinous bronchioloalveolar carcinomas, 9 STK11 and TP53 mutations in solid adenocarcinomas, 2 and EML4-ALK genes fusion in acinar tumors. 5 Overall, these data suggest that a more systematic comprehensive histologic assessment of NSCLC may predict specific molecular alterations.
Pathologic evaluation of multiple NSCLC plays an important role in distinguishing intrapulmonary metastases versus metachronous or synchronous primaries. This distinction is of great clinical importance as it influences lung cancer staging and therapeutic strategy. Historically this has been achieved using clinicopathologic criteria designed by Martini and Melamed (Table 1) . 6 In this classification, there was no distinction of histology beyond major subtype except for adenocarcinoma and bronchiolar carcinoma. 6 Since the 1970s when these criteria were proposed, a variety of molecular tools have become available such as mutation profiling and arraybased comparative hybridization techniques that provide a reliable and powerful way to evaluate the clonal relationships between multiple tumors. 12, 19 Moreover, adenocarcinoma has replaced squamous carcinoma as the most common histologic subtype, 16 and we have learned that adenocarcinomas show frequent histologic heterogeneity.
In this study, we took advantage of a cohort of patients with multiple NSCLC tumors that were previously annotated molecularly using genomic and mutational profiling 4 to evaluate the value of comprehensive histologic assessment in differentiating multiple primary tumors from metastases. We also applied the concept of comprehensive histologic assessment to the squamous cell carcinomas in this cohort to see if it provided any useful information.
MATERIALS AND METHODS

Tumor Specimens
Eligible patients for this study were identified using Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology and Thoracic Surgery Service databases. We included all consecutive patients who received multiple operations for NSCLC from 1999 to 2007, and for whom tumor frozen specimens from at least 2 tumors were banked separately. The use of these specimens was approved by the Institutional Review Board of MSKCC. Clinical information was obtained from patients medical records, and paired tumors were characterized as multiple primaries or metastases using the standard Martini-Melamed criteria. 6 
Molecular Characterization
Detailed molecular analyses have been reported previously. 4 Briefly, we used mutational and genomic profiling techniques to assess the clonal relationships between multiple tumors from individual patients. Using mass spectrometry-based genotyping (Sequenom, San Diego, CA), mutational profiling of selected genes was performed for activating mutations in 9 genes encoding components of the EGFR signaling pathway 2 : EGFR, Tumor pairs with similar mutations were diagnosed as metastases and those with different mutations as multiple primary tumors. 1 For genomic profiling, DNA from each tumor was hybridized to Agilent 244K comparative genomic hybridization (CGH) arrays (Agilent Technologies, Santa Clara, CA). This array identifies copy number alterations on 236,000 coding and noncoding loci across the genome. Gains and losses were compared for paired tumors according to a previously described method that calculates the relative chances that at least one of the observed concordant genomic alterations is of clonal origin and classifies tumor pairs as clonal metastases or as independent multiple primary tumors. 12 Intermediate results were considered ''equivocal.''
Comprehensive Histologic Assessment
Location, number, and size of the tumors were retrieved from pathology reports. Two pathologists (C.D. and W.D.T.) blindly reviewed hematoxylin and eosin (H&E)-stained slides from (1) formalin-fixed, paraffinembedded tumor blocks used for the routine surgical pathology diagnosis, and (2) from cryostat sections of frozen tumor specimens collected for molecular analyses (1 slide/sample). Samples used for molecular analyses were selected for tumor content >70%. Histologic classification was carried out according to the 2004 WHO classification, 20 with comprehensive histologic subtyping as previously described by Motoi et al, for mixed subtype adenocarcinomas. 9 Briefly, we semiquantitatively evaluated the relative percentage of each histologic subtype, including the acinar, papillary, bronchioloalveolar, solid, and micropapillary components, in 10% increments. The micropapillary pattern consisted of small papillary tufts observed within alveolar spaces or encased within thin walls of connective tissue, lacking fibrovascular cores. 7 On slides from paraffinembedded specimens, tumors were also assessed for variants, that is, mucinous, fetal, colloid, signet ring, or clear cell changes for adenocarcinomas, and papillary, clear cell, basaloid, or sarcomatoid features in squamous cell carcinomas.
The overall method of comprehensive histologic assessment included evaluation of not only the percentages of histologic subtypes, but also additional histologic features such as grade, cytologic features as well as stromal characteristics such as collagen, inflammation, lymphoid hyperplasia, and/or necrosis were also considered in comparing the tumors ( Fig. 1 ). For squamous cell carcinoma, detailed histologic assessment was made according to the cytologic morphology, amount of keratinization, appearance of the stroma, necrosis, as well the presence of histologic components such as basaloid, clear cell, papillary or sarcomatoid carcinoma. Paired tumors exhibiting similar histologic features were considered as metastases, and those showing different histologic features as multiple primaries ( Fig. 1 ).
Time-to-Progression Analysis
Time-to-progression was defined as the time interval between the resection of the second (or third) tumor and first recurrence. All patients were included in the statistical calculations. Time-to-progression was assessed using the Kaplan-Meier method. The influence of classifications on time-to-progression was studied using the log-rank test. Results were considered significant at the 0.05 level. Statistical analyses were performed using the SPSS software program (Chicago, IL), version 17.0. Patient outcome was regarded as another method of evaluation of the clinical relevance of the various approaches to classification of the paired tumors. According to this approach, recurrence versus lack of recurrence was regarded to favor metastases versus synchronous primaries, respectively.
RESULTS
Selection of Samples and Clinical Characteristics
The case selection method and overall clinical features of these cases have been previously reported elsewhere. 4 Forty-two NSCLCs from 20 patients were studied, including 18 patients with 2 tumors and 2 patients with 3 tumors. This cohort allowed a total of 24 pair comparisons. In cases with 2 tumors there was 1 comparison, but in cases with 3 tumors, there were 3 comparisons. Tumors were synchronous in 6 patients and metachronous in 14 patients. Median interval between metachronous tumors was 24 months. Using the Martini-Melamed criteria, paired tumors were characterized as multiple primary NSCLCs in 21 cases and as intrapulmonary metastases in 3 cases. The mean follow-up time for each patient was 4.4 years (range, 1.6-10.5 y). Three patients with synchronous tumors and 1 patient with metachronous tumors received adjuvant chemotherapy.
Molecular Characterization
Detailed results from molecular characterization of these multiple tumors have been reported separately. 4 Briefly, genomic profiling was informative for 22 tumor pair comparisons, leading to a diagnosis of metastases in 4 cases and of multiple primaries in 14 cases. The conclusion was equivocal in 4 comparisons, mostly because of a high background noise in the genomic profile data.
By mutational profiling, matching point mutations were observed in 8 tumor pairs, including the 4 pairs classified as metastases by genomic profiling and these 4 ''equivocal'' cases. Discordant mutations were observed in 9 paired tumors. Mutational status was consistent with the genomic profile in all of the 13 cases for which both data were available. This suggests that results from mutational analysis may be a surrogate for genomic profiling in the setting multiple lung tumors. 4 We then integrated the genomic and mutational data to assess clonality between these pairs of multiple primaries. The molecular consensus was first based on genomic profiling, and only if array-CGH data were not conclusive (ie, in the 4 ''equivocal'' cases), on mutational analyses. Using this approach, genomic and mutational data led to a diagnosis of multiple primaries in 14 cases and of metastases in 8 cases. In the 2 paired comparisons that could not be assessed by array-CGH, genotyping did not disclose any mutation, and a molecular consensus diagnosis could not be made.
Consensus molecular characterization contradicted the Martini-Melamed diagnosis in 7 (32%) of the 22 comparisons, identifying metastases in 6 cases regarded clinically as multiple primaries, and multiple primaries in 1 case regarded as metastases. 4 
Comprehensive Histologic Assessment Surgical Pathology Slides
Comprehensive histologic assessment was carried out on H&E slides from formalin-fixed, paraffin-embedded tumor specimens ( Figs. 2-4 ). The number of slides from each tumor ranged from 2 to 12. Adenocarcinoma was the most frequent histologic type found in 32 (76%) of the 42 tumors. Major histologic subtype was papillary in 18 (56%), acinar in 4 (13%), solid in 5 (16%), bronchioloalveolar in 3 (9%), and micropapillary in 2 (6%) tumors. Eight tumors were of squamous cell histology, and 2 tumors were large-cell neuroendocrine carcinoma. The results of comprehensive histologic assessment are shown in Table 2 and Figure 5 .
Comparison of 2 adenocarcinomas, however, was complex and required incorporation of multiple pieces of morphologic information. One of the most useful ways to compare 2 adenocarcinomas to determining whether 2 tumors were morphologically similar or different was the recording of percentages of histologic subtypes. In all 9 pairs where the adenocarcinomas were regarded as different [cases 1 to 4, 5 (tumor A vs. tumor C), 11, 12, 14, and 18], the percentages were different between the paired tumors, even if they had the same predominant histologic subtype ( Table 2 , Fig. 5 ). In addition, in one of the paired tumors from 1 case each, the presence of lymphoid hyperplasia in the stroma (case 1), or mucinous cells and fetal adenocarcinoma (case 18) in one of the paired tumors, also helped to determine the tumors were morphologically different. However, even when 2 adenocarcinomas were regarded as similar (7 pairs: cases 6, 7, 9, 13, and 20: tumor A vs. tumor C, tumor B vs. tumor C, tumor A vs. tumor B), they did not always have exactly the same percentages of histologic subtypes, and other histologic features were needed to compare the tumors. In all 7 cases, tumors regarded to be similar had the same most prominent subtype. However, in 6 cases, there were differences in the distribution of the other histologic subtypes, but because of similar cytologic features along with the common presence of signet ring (case 6), mucinous cells (case 7), a ''miliary''-like extension in the lung parenchyma (case 13) ( Fig. 6 ), or clear cells (case 20) (Fig. 7) , these were considered as being similar (Fig. 5 ).
For the 3 cases of paired squamous cell carcinomas (cases 10, 15, and 19), 2 pairs were regarded as being morphologically different whereas 1 pair was interpreted to be the same. In case 15, the presence of necrosis in only one of the tumors helped to determine they were Metachronous (25.1 mo) A LUL SCC n/a n/a n/a n/a n/a Desmoplastic stroma necrosis Different B RLL SCC n/a n/a n/a n/a n/a Inflammatory stroma 11
Metachronous ( Metachronous (50.2 mo) A LUL SCC n/a n/a n/a n/a n/a Different B RUL SCC n/a n/a n/a n/a n/a Necrosis 16
Metachronous (53.6 mo) A LLL SCC n/a n/a n/a n/a n/ Metachronous (13.5 mo) A LLL SCC n/a n/a n/a n/a n/a Sarcomatoid/basaloid Similar B LLL SCC n/a n/a n/a n/a n/a Sarcomatoid/basaloid 20
Metachronous ( morphologically different. In case 10, it was the architecture of the stroma and the extent of necrosis that helped to distinguish the 2 tumors (Fig. 8) . In case 19, it was the presence of both sarcomatoid and basaloid components in each tumor that helped to determine the tumors were the same histologically ( Fig. 9 ). In both of these tumors, the sarcomatoid component was less than 10% of the entire tumor, so they were not regarded as a pleomorphic carcinoma.
In summary, comprehensive histologic comparison of paired tumors was different in 16 cases, and similar in 8 cases. Considering histologically different tumors as multiple primaries, and similar tumors as metastases, comprehensive histologic assessment was consistent with the molecular characterization in 20 (91%) of the 22 pairs comparisons ( Table 3 ). In 1 pair (case 5, tumor A vs. tumor C), molecular consensus was actually supported only by mutational profiling, as array-CGH interpretation was equivocal. In this case, the molecular consensus was based on the presence of an identical KRAS G12C mutation in both tumors, but comprehensive histologic typing demonstrated striking morphologic differences and furthermore the tumors were contralateral, favoring synchronous primaries. In the second case (case 19), array CGH favored the 2 tumors were different, but both squamous cell carcinomas had a very distinctive basaloid and focally sarcomatoid pattern, leading the comprehensive histologic interpretation to favor intrapulmonary metastasis. This patient developed recurrent lung cancer 14 months after tumor B. Interestingly, the 2 discrepant cases were also misclassified using the standard Martini-Melamed criteria. Overall, comprehensive histologic assessment contradicted the Martini-Melamed clinical criteria in 5 (21%) cases; in these 5 cases, comprehensive histologic assessment was concordant with the molecular consensus.
Frozen Section Slides
Evaluation of the frozen section slides from the tissue used for molecular analyses was not as accurate as the interpretation of the formalin-fixed, paraffinembedded sections used for surgical pathology diagnosis (Supplemental Table 1 , Supplemental Digital content 1, http://links.lww.com/PAS/A34). Especially, adenocarcinoma and squamous cell carcinoma histologic subtypes could not be reliably recognized. For adenocarcinomas, generally the major subtypes identified in the permanent sections were seen in the frozen sections 21 cases (66%). In 11 (34%) cases, the major subtype seen on permanent sections was not seen on frozen section. These differences were interpreted to be because of sampling issues or frozen section artifacts.
Overall, the accuracy of comprehensive histologic examination was lower when using H&E slides from frozen tumor tissue specimens, as results were consistent with the molecular characterization in 14 (64%) pairs, discordant in 6 (27%) pairs, and not possible in 2 cases (involving squamous cell carcinomas) ( Table 3) .
Time-to-Progression
Overall, median time-to-progression from the last resection was 25.6 months (95% confidence interval, 0-51.8 mo). According to the Martini-Melamed criteria, molecular characterization, and comprehensive histologic assessment, median time-to-progression was 35.1 months for multiple primaries, and 4.6, 7.4, and 7.4 months for metastases, respectively (P = 0.052; P = 0.013; P = 0.001, respectively) ( Fig. 10) . The reason for the better survival according to comprehensive histologic assessment compared with molecular characterization is because the clinical outcome in cases 5 and 19, was more consistent with the histologic rather than the molecular interpretation. These data suggest that molecular characterization and comprehensive histologic assessment might be more relevant than the Martini-Melamed criteria alone to distinguish multiple primary tumors from metastases.
DISCUSSION
The major purpose of this study was to investigate whether detailed surgical pathology assessment of multiple NSCLC could predict whether the tumors were intrapulmonary metastases versus synchronous primaries. In this study, using routine light microscopic pathologic assessment of multiple lung carcinomas with comprehensive histologic subtyping in addition to assessment of other detailed tumor histologic characteristics, we showed that the accuracy of pathology to differentiate multiple primary tumors from metastases, as defined by molecular characterization, was as high as 91%. Furthermore, the significantly worse outcome for patients with tumors regarded as metastases compared with multiple primary tumors, according to both surgical pathology as well as molecular assessment supports that these assessments were clinically relevant. Both molecular and comprehensive histologic assessment seemed to more accurately classify multiple tumors than the Martini-Melamed criteria.
In our cohort, the standard Martini-Melamed criteria correlated with molecular characterization only in 68% of cases. Not only is adenocarcinoma currently the most common histologic subtype of lung cancer, in contrast to the time when Martini and Melamed proposed their criteria and squamous cell carcinoma was most common, but recent surgical series report that most multiple lung cancers are adenocarcinomas. 11, 14, 15, 17 In the Martini Melamed criteria, tumors were distinguished if they were in separate WHO major histologic subtypes such as adenocarcinoma, or squamous cell carcinoma but at that time, the 1967 WHO classification was in effect and there were only 2 types of lung adenocarcinoma recognized: bronchiolar and adenocarcinoma. 21 In addition, the current 2004 WHO classification provides limited information when comparing multiple lung adenocarcinomas, as over 90% of all tumors are classified as the mixed subtype. 20 Our results suggest that comprehensive histologic assessment supersedes the Martini-Melamed clinical criteria to differentiate multiple primary tumors from metastases. 9 However, this is a complex issue that requires assessment not only of percentages of the histologic subtypes in lung adenocarcinomas, 10 but also the recording of additional histologic details (Fig. 1) . It is expected that there would be some variation in percentages even in identical tumors based on differences in sampling of the gross specimen. Furthermore in lung carcinomas with a poorly differentiated component, one might expect to see a greater proportion of the poorly differentiated histology in the metastatic lesion.
The clinical significance of comprehensive histologic assessment has not been tested in squamous cell carcinomas. Although these tumors do not typically show the same degree of heterogeneity as lung adenocarcinomas, there can be distinctive histologic characteristics that allow for comparison between tumor pairs such as degree of keratinization, amount of necrosis, quality of stroma including pattern of desmoplasia or inflammation as well as the presence of currently recognized variants including clear cell, papillary, basaloid or sarcomatoid patterns. 8 Although we only had 3 patients with paired squamous cell carcinomas in this study, there were distinctive histologic features in each of these patients that allowed for recognition that tumors were different in 2 cases or similar in 1. Despite this small number of cases, these findings suggest that attention to details of morphologic characteristics even for some squamous cell carcinomas may allow pathologists to distinguish whether tumors are similar or different.
We had more difficulty in accurately classifying multiple lung carcinomas as independent primaries versus metastases when reviewing cryostat sections from frozen specimens, as compared with the slides from complete surgical pathology specimens based on formalin-fixed, paraffin-embedded samples. Although the frozen sections examined were from the tissue used for molecular analysis, these findings are applicable to the intraoperative consultation setting where pathologists may be asked to address the problem of similar versus different morphology on frozen sections. It is understandable that the data would be less accurate, due to limited histologic sampling of a single piece of tissue, making it more difficult to assess adenocarcinoma percentages of histologic subtypes. This is especially true in this study, because most of the frozen specimens were smaller than 0.5 cm. In addition, poorly differentiated tumors such as adenosquamous carcinoma and large-cell neuroendocrine carcinoma as well as some morphologic variants of adenocarcinoma, including clear cell or signet-ring patterns, are difficult to identify in nonfixed tissues. Therefore, we would recommend caution in the frozen section setting for comparing separate lung cancers.
Comprehensive histologic assessment may also have advantages over molecular analyses, because it is a more rapid and inexpensive method which is feasible in a routine pathology practice setting. Compared with array-CGH, comprehensive histologic assessment led to a more reliable diagnosis, as array-CGH was uninformative in some cases based on poor DNA quality. Moreover, compared with the mutational profiling performed in this study, comprehensive histologic assessment was also more informative, as many tumors were wildtype for all mutations tested, making clonality difficult to establish. Although one could also consider applying immunohistochemistry and mucin stains to this problem, we found light microscopy alone was sufficient in the cases we studied. Comprehensive histologic assessment is a relatively new concept that needs further study, not only in the setting of multiple lung tumors, but also in the context of histologic and molecular classification of lung adenocarcinomas and squamous cell carcinomas. 9 Its reproducibility among pathologists remains to be established, although for the problem of multiple lung cancers, reproducibility between different pathologists should not be an issue if in a single patient the same pathologist is able to review all the available tumors. This also underscores the importance of obtaining the histologic slides of all resected tumors for comparison when assessing the question of metastatic versus synchronous or metachronous primaries. If slides are not available from a lung cancer that has been previously diagnosed with comprehensive histologic assessment, it is possible in some cases from the report alone for a pathologist to make an educated assessment whether 2 tumors might be similar or different morphologically. As at the moment, there are no known specific molecular correlations with histologic patterns, comprehensive histologic subtyping cannot be used to predict the underlying genetic differences/similarities among tumors from different patients. Finally, if only small biopsies are available rather than surgical resection specimens, mutational profiling may represent the only way to characterize multiple lung tumors.
In summary, based on a well characterized dataset with clinical and detailed molecular data, we have identified a way to turn the often frustrating problem of histologic heterogeneity of lung adenocarcinoma into a powerful tool to accurately classify multiple lung cancers as synchronous primaries versus metastasis. To our surprise, we also found there may be a way to apply this approach to squamous cell carcinomas in addition to adenocarcinomas. This has great clinical implications for staging and therapeutic management of lung cancer patients with multiple tumors. Overall, we recommend that comprehensive histologic assessment could be considered as a promising way to determine whether multiple adenocarcinomas and squamous cell carcinomas are metastatic versus synchronous or metachronous primaries. Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem. A limitation of this study is the small number of patients, but our findings in a highly characterized clinical and molecular dataset are compelling enough to warrant testing in larger datasets.
